bioMérieux S.A. (EPA:BIM)
France · Delayed Price · Currency is EUR 74.20
+1.10 (1.50%)
Aug 20, 2026, 5:22 PM CET
bioMérieux Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,991 | 4,070 | 3,980 | 3,675 | 3,589 | 3,376 | |
Revenue Growth | -3.18% | 2.26% | 8.30% | 2.38% | 6.31% | 8.27% |
Cost of Revenue | 1,751 | 1,761 | 1,765 | 1,617 | 1,580 | 1,375 |
Gross Profit | 2,240 | 2,309 | 2,215 | 2,057 | 2,009 | 2,001 |
Selling, General & Admin | 1,087 | 1,111 | 1,098 | 1,021 | 954.7 | 815.6 |
Research & Development | 515.4 | 507.4 | 491.5 | 460.1 | 446.6 | 385.8 |
Amortization of Goodwill & Intangibles | - | - | - | - | - | 30.5 |
Other Operating Expenses | -31.5 | -37.8 | -46.9 | -33 | -43.6 | -44.6 |
Operating Expenses | 1,600 | 1,614 | 1,577 | 1,488 | 1,396 | 1,187 |
Operating Income | 639.8 | 694.8 | 637.9 | 569 | 613 | 813.5 |
Interest Expense | -16.1 | -15.8 | -16 | -15.8 | -4.1 | -9.1 |
Interest & Investment Income | 14.5 | 14.3 | 14.4 | 12.5 | 1.2 | 1.7 |
Earnings From Equity Investments | - | - | - | - | - | -0.7 |
Currency Exchange Gain (Loss) | 2.3 | 9.9 | -4.3 | 4.7 | -1.4 | -4.3 |
Other Non Operating Income (Expenses) | 0.4 | 0.4 | 1.7 | 0.2 | -2.2 | 1.3 |
EBT Excluding Unusual Items | 640.9 | 703.6 | 633.7 | 570.6 | 606.5 | 802.4 |
Merger & Restructuring Charges | -14.5 | -15.1 | -0.3 | -0.3 | -9.6 | -0.9 |
Impairment of Goodwill | - | - | - | -94.9 | -29 | -4.6 |
Gain (Loss) on Sale of Investments | - | - | - | -3.4 | - | 0.6 |
Gain (Loss) on Sale of Assets | - | - | - | - | 12.8 | - |
Asset Writedown | -13.3 | -158.8 | -48.8 | -34.7 | - | -23.7 |
Other Unusual Items | -6 | -4 | -5.2 | - | - | - |
Pretax Income | 607.1 | 525.7 | 579.4 | 437.3 | 580.7 | 773.8 |
Income Tax Expense | 145 | 128.8 | 154.3 | 114.5 | 140.1 | 175.6 |
Earnings From Continuing Operations | 462.1 | 396.9 | 425.1 | 322.8 | 440.6 | 598.2 |
Minority Interest in Earnings | 0.5 | 0.6 | 7.1 | 34.8 | 11.8 | 2.9 |
Net Income | 462.6 | 397.5 | 432.2 | 357.6 | 452.4 | 601.1 |
Net Income to Common | 462.6 | 397.5 | 432.2 | 357.6 | 452.4 | 601.1 |
Net Income Growth | 22.41% | -8.03% | 20.86% | -20.95% | -24.74% | 48.64% |
Shares Outstanding (Basic) | 118 | 118 | 118 | 118 | 118 | 118 |
Shares Outstanding (Diluted) | 119 | 119 | 119 | 119 | 118 | 119 |
Shares Change | -0.30% | 0.06% | -0.03% | 0.32% | -0.39% | 0.20% |
EPS (Basic) | 3.93 | 3.37 | 3.67 | 3.03 | 3.84 | 5.08 |
EPS (Diluted) | 3.90 | 3.34 | 3.64 | 3.01 | 3.82 | 5.06 |
EPS Growth | 23.04% | -8.24% | 20.93% | -21.20% | -24.51% | 48.39% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 583 | 453.1 | 321.5 | 107.1 | 188.4 | 534.6 |
Free Cash Flow Per Share | 4.92 | 3.81 | 2.71 | 0.90 | 1.59 | 4.50 |
Dividend Per Share | 0.980 | 0.980 | 0.900 | 0.850 | 0.850 | 0.850 |
Dividend Growth | 8.89% | 8.89% | 5.88% | 0% | 0% | 37.10% |
Gross Margin | 56.13% | 56.73% | 55.66% | 55.99% | 55.97% | 59.26% |
Operating Margin | 16.03% | 17.07% | 16.03% | 15.48% | 17.08% | 24.09% |
Profit Margin | 11.59% | 9.77% | 10.86% | 9.73% | 12.61% | 17.80% |
Free Cash Flow Margin | 14.61% | 11.13% | 8.08% | 2.92% | 5.25% | 15.83% |
EBITDA | 1,051 | 1,130 | 948.1 | 857.8 | 852.6 | 1,005 |
EBITDA Margin | 26.33% | 27.76% | 23.82% | 23.34% | 23.76% | 29.77% |
D&A For EBITDA | 410.8 | 434.9 | 310.2 | 288.8 | 239.6 | 191.6 |
EBIT | 639.8 | 694.8 | 637.9 | 569 | 613 | 813.5 |
EBIT Margin | 16.03% | 17.07% | 16.03% | 15.48% | 17.08% | 24.09% |
Effective Tax Rate | 23.88% | 24.50% | 26.63% | 26.18% | 24.13% | 22.69% |